Familial Chylomicronemia

Also known as: Familial Chylomicronemia Syndrome (FCS) / Familial Chylomicronemia Syndrome / Chylomicronemia, Familial / Familial chylomicronemia syndrome (disorder) / Familial chylomicronaemia syndrome / Hyperchylomicronemia / Lipoprotein-lipase deficiency / Type I hyperlipoproteinemia / Hyperlipoproteinemia Type I / Familial lipoprotein lipase deficiency (disorder) / Familial lipoprotein lipase deficiency with type I phenotype (disorder) / Familial hyperchylomicronemia (disorder) / Type I hyperlipoproteinaemia / Pure hyperglyceridemia / Type IV lipidemia / Type IV lipidaemia / Fredrickson Type IV lipidaemia / Endogenous hyperlipidemia (disorder) / Fredrickson type IV hyperlipoproteinemia (disorder) / Fredrickson Type IV lipidemia / Familial hypertriglyceridaemia / Familial hypertriglyceridemia / Familial hypertriglyceridemia (disorder) / Pure hyperglyceridemia (disorder) / Type IV hyperlipidaemia / Type IV hyperlipidemia / Pure hyperglyceridaemia / Type IV hyperlipoproteinaemia / Hyperlipoproteinemia Type IV / Type IV hyperlipoproteinemia

DrugDrug NameDrug Description
DB15067VolanesorsenAn antisense oligonucleotide indicated to treat familial chylomicronemia.
DrugDrug NameTargetType
DB15067VolanesorsenApolipoprotein C-IIItarget
DrugDrug NamePhaseStatusCount
DB17625ARO-APOC31Completed1
DB17625ARO-APOC33Active Not Recruiting1
DB17625ARO-APOC33Not Yet Recruiting1
DB12866Pradigastat3Completed1
DB15067Volanesorsen3Completed2
DB15067VolanesorsenNot AvailableNo Longer Available1